TY - JOUR
T1 - Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries
T2 - a population-based study of countries in the Organisation for Economic Co-operation and Development
AU - King, James A.
AU - Underwood, Fox E.
AU - Panaccione, Nicola
AU - Quan, Josh
AU - Windsor, Joseph W.
AU - Kotze, Paulo G.
AU - Ng, Siew C.
AU - Ghosh, Subrata
AU - Lakatos, Peter L.
AU - Jess, Tine
AU - Panaccione, Remo
AU - Seow, Cynthia H.
AU - Ben-Horin, Shomron
AU - Burisch, Johan
AU - Colombel, Jean Frédéric
AU - Loftus, Edward V.
AU - Gearry, Richard
AU - Halfvarson, Jonas
AU - Kaplan, Gilaad G.
N1 - Funding Information:
PGK reports fees for participation on advisory boards and speaking fees from AbbVie, Janssen, Takeda, Pfizer, and Union Chimique Belge (UCB), outside the submitted work. SG reports grants and personal fees from AbbVie and personal fees from Janssen and Takeda, outside the submitted work. CHS reports grants and personal fees from Janssen and personal fees from AbbVie Takeda, Ferring, Shire, and Pfizer, outside the submitted work. J-FC reports grants from AbbVie, Janssen, and Takeda, and was a consultant and speaker for Celgene and Ferring Pharmaceuticals; a shareholder for Intestinal Biotech Development and Genfit; and a consultant for Amgen, Boehringer-Ingelheim, Celltrion, Enterome, Genentech, MedImmune, Merck, Pfizer, Protagonist, Second Genome, Seres Therapeutics, Shire, Takeda, Theradiag, Theravance Biopharma, Eli Lilly, Nextbiotix, Novartis, Otsuka, Arena Pharmaceutical, Gilead, and Zealand Pharmaceutical, outside the submitted work. EVLJr reports grants and personal fees from AbbVie, Amgen, Celgene, Janssen, Takeda, and UCB; grants from Gilead, Genentech, Robarts Clinical Trials, and MedImmune; and personal fees from Eli Lilly, Celltrion, Allergan, and Bristol-Myers Squibb, outside the submitted work. JB reports personal fees from AbbVie, Janssen, Celgene, Merck, and Pfizer, and grants and personal fees from Takeda, outside the submitted work. GGK reports honoraria for speaking or consultancy from Janssen, AbbVie, and Pfizer, and research support from Janssen, AbbVie, GlaxoSmithKline, Merck, and Shire. He has shares in a patent (number 62/555 397). All other authors declare no competing interests.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/4
Y1 - 2019/4
N2 - Background: Hospitalisation rates for inflammatory bowel disease (IBD) vary across the world. We aimed to investigate temporal patterns of hospitalisation for IBD in member countries of the Organisation for Economic Co-operation and Development (OECD). Methods: From the OECD database, we assessed IBD-related hospitalisation rates (expressed as annual rates per 100 000 inhabitants) for 34 countries from 1990 to 2016. We calculated mean hospitalisation rates for the period 2010–15 and used joinpoint regression models to calculate average annual percentage changes with 95% CIs. Findings: Mean hospitalisation rates for IBD from 2010 to 2015 were highest in North America (eg, 33·9 per 100 000 in the USA), Europe (eg, 72·9 per 100 000 in Austria), and Oceania (eg, 31·5 per 100 000 in Australia). Hospitalisation rates for IBD were stabilising or decreasing over time in many countries in these regions but increasing in others. Countries in Asia and Latin America and the Caribbean had the lowest IBD-related hospitalisation rates but the greatest increases in rates over time. For example, Turkey had an annual hospitalisation rate of 10·8 per 100 000 inhabitants and an average annual percentage change of 10·4% (95% CI 5·2–15·9). Similarly, Chile had an annual hospitalisation rate of 9·0 per 100 000 inhabitants and an average annual percentage change of 5·9% (4·9–7·0). Interpretation: Hospitalisation rates for IBD are high in western countries but are typically stabilising or decreasing, whereas rates in many newly industrialised countries are rapidly increasing, which reflects the known increase in IBD prevalence in these countries. Potential explanations for these trends include changes in the epidemiology of IBD, health-care delivery, and infrastructure in these countries, as well as overall country-specific patterns in hospitalisations and differences between countries in data collection methods. Funding: None.
AB - Background: Hospitalisation rates for inflammatory bowel disease (IBD) vary across the world. We aimed to investigate temporal patterns of hospitalisation for IBD in member countries of the Organisation for Economic Co-operation and Development (OECD). Methods: From the OECD database, we assessed IBD-related hospitalisation rates (expressed as annual rates per 100 000 inhabitants) for 34 countries from 1990 to 2016. We calculated mean hospitalisation rates for the period 2010–15 and used joinpoint regression models to calculate average annual percentage changes with 95% CIs. Findings: Mean hospitalisation rates for IBD from 2010 to 2015 were highest in North America (eg, 33·9 per 100 000 in the USA), Europe (eg, 72·9 per 100 000 in Austria), and Oceania (eg, 31·5 per 100 000 in Australia). Hospitalisation rates for IBD were stabilising or decreasing over time in many countries in these regions but increasing in others. Countries in Asia and Latin America and the Caribbean had the lowest IBD-related hospitalisation rates but the greatest increases in rates over time. For example, Turkey had an annual hospitalisation rate of 10·8 per 100 000 inhabitants and an average annual percentage change of 10·4% (95% CI 5·2–15·9). Similarly, Chile had an annual hospitalisation rate of 9·0 per 100 000 inhabitants and an average annual percentage change of 5·9% (4·9–7·0). Interpretation: Hospitalisation rates for IBD are high in western countries but are typically stabilising or decreasing, whereas rates in many newly industrialised countries are rapidly increasing, which reflects the known increase in IBD prevalence in these countries. Potential explanations for these trends include changes in the epidemiology of IBD, health-care delivery, and infrastructure in these countries, as well as overall country-specific patterns in hospitalisations and differences between countries in data collection methods. Funding: None.
UR - http://www.scopus.com/inward/record.url?scp=85062361281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062361281&partnerID=8YFLogxK
U2 - 10.1016/S2468-1253(19)30013-5
DO - 10.1016/S2468-1253(19)30013-5
M3 - Article
C2 - 30765267
AN - SCOPUS:85062361281
SN - 2468-1253
VL - 4
SP - 287
EP - 295
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
IS - 4
ER -